Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients

Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chinese medical journal 2014, Vol.127 (20), p.3645-3650
Hauptverfasser: Wang, Jianglin, Guo, Ren, Liu, Shikun, Chen, Qingjie, Zuo, Shanru, Yang, Meng, Zuo, Xiaocong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3650
container_issue 20
container_start_page 3645
container_title Chinese medical journal
container_volume 127
creator Wang, Jianglin
Guo, Ren
Liu, Shikun
Chen, Qingjie
Zuo, Shanru
Yang, Meng
Zuo, Xiaocong
description Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.
doi_str_mv 10.3760/cma.j.issn.0366-6999.20141176
format Article
fullrecord <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_zhcmj201420022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>662852132</cqvip_id><wanfj_id>zhcmj201420022</wanfj_id><sourcerecordid>zhcmj201420022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</originalsourceid><addsrcrecordid>eNo9kUFv1DAQhS0EokvhL6AICcQlwZ6JvfGBA6ooIIq4wIWL5TjOrqPETu1EqPx6HO1uTyN5vpk3fo-Qt4xWuBf0g5l0NVQuJV9RFKIUUsoKKKsZ24snZAe8hpKLmj0lu0fgirxIaaAUON-L5-QKODIBNe7Inx9htGYddSwma47auzSlIvTF7XdORel8txrbFceH2cbF-uSCL5wvUhhdV4R40L5YovZpHrVf9LK151ysX9JL8qzXY7KvzvWa_L79_Ovma3n388u3m093pamxWUoJFmRtbc9tS2XfmRa11ADIdNMDSomdaHgvu7bmiDWi1dDmd2YpctlRvCbvTnv_at9rf1BDWKPPiurf0UzD5g3kr0MG35_AOYb71aZFTS4ZO-bTbViTYoKBbDjuWUY_nlATQ0rR9mqObtLxQTGqthxUzkENastBbTarzWZ1ySHPvz5Lre1ku8fpi_EZeHMWOAZ_uHf57AsjBDQcGAL-B_h8kp4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1612985371</pqid></control><display><type>article</type><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</creator><creatorcontrib>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</creatorcontrib><description>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.3760/cma.j.issn.0366-6999.20141176</identifier><identifier>PMID: 25316243</identifier><language>eng</language><publisher>China: Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</publisher><subject>FK506 ; FKBP12 ; Humans ; Hypertension - chemically induced ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Organ Transplantation - adverse effects ; Tacrolimus - adverse effects ; Tacrolimus - therapeutic use ; 分子机制 ; 器官移植 ; 妊高征 ; 实体 ; 患者 ; 蛋白激酶C</subject><ispartof>Chinese medical journal, 2014, Vol.127 (20), p.3645-3650</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</citedby><cites>FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85656X/85656X.jpg</thumbnail><link.rule.ids>314,780,784,864,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25316243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jianglin</creatorcontrib><creatorcontrib>Guo, Ren</creatorcontrib><creatorcontrib>Liu, Shikun</creatorcontrib><creatorcontrib>Chen, Qingjie</creatorcontrib><creatorcontrib>Zuo, Shanru</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Zuo, Xiaocong</creatorcontrib><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><title>Chinese medical journal</title><addtitle>Chinese Medical Journal</addtitle><description>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</description><subject>FK506</subject><subject>FKBP12</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Organ Transplantation - adverse effects</subject><subject>Tacrolimus - adverse effects</subject><subject>Tacrolimus - therapeutic use</subject><subject>分子机制</subject><subject>器官移植</subject><subject>妊高征</subject><subject>实体</subject><subject>患者</subject><subject>蛋白激酶C</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kUFv1DAQhS0EokvhL6AICcQlwZ6JvfGBA6ooIIq4wIWL5TjOrqPETu1EqPx6HO1uTyN5vpk3fo-Qt4xWuBf0g5l0NVQuJV9RFKIUUsoKKKsZ24snZAe8hpKLmj0lu0fgirxIaaAUON-L5-QKODIBNe7Inx9htGYddSwma47auzSlIvTF7XdORel8txrbFceH2cbF-uSCL5wvUhhdV4R40L5YovZpHrVf9LK151ysX9JL8qzXY7KvzvWa_L79_Ovma3n388u3m093pamxWUoJFmRtbc9tS2XfmRa11ADIdNMDSomdaHgvu7bmiDWi1dDmd2YpctlRvCbvTnv_at9rf1BDWKPPiurf0UzD5g3kr0MG35_AOYb71aZFTS4ZO-bTbViTYoKBbDjuWUY_nlATQ0rR9mqObtLxQTGqthxUzkENastBbTarzWZ1ySHPvz5Lre1ku8fpi_EZeHMWOAZ_uHf57AsjBDQcGAL-B_h8kp4</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Wang, Jianglin</creator><creator>Guo, Ren</creator><creator>Liu, Shikun</creator><creator>Chen, Qingjie</creator><creator>Zuo, Shanru</creator><creator>Yang, Meng</creator><creator>Zuo, Xiaocong</creator><general>Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>2014</creationdate><title>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</title><author>Wang, Jianglin ; Guo, Ren ; Liu, Shikun ; Chen, Qingjie ; Zuo, Shanru ; Yang, Meng ; Zuo, Xiaocong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-92e294eef5eb09fdcb3a9a2231a8f23993d685f9db4533433ea2b2391e0359d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>FK506</topic><topic>FKBP12</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Organ Transplantation - adverse effects</topic><topic>Tacrolimus - adverse effects</topic><topic>Tacrolimus - therapeutic use</topic><topic>分子机制</topic><topic>器官移植</topic><topic>妊高征</topic><topic>实体</topic><topic>患者</topic><topic>蛋白激酶C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jianglin</creatorcontrib><creatorcontrib>Guo, Ren</creatorcontrib><creatorcontrib>Liu, Shikun</creatorcontrib><creatorcontrib>Chen, Qingjie</creatorcontrib><creatorcontrib>Zuo, Shanru</creatorcontrib><creatorcontrib>Yang, Meng</creatorcontrib><creatorcontrib>Zuo, Xiaocong</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jianglin</au><au>Guo, Ren</au><au>Liu, Shikun</au><au>Chen, Qingjie</au><au>Zuo, Shanru</au><au>Yang, Meng</au><au>Zuo, Xiaocong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chinese Medical Journal</addtitle><date>2014</date><risdate>2014</risdate><volume>127</volume><issue>20</issue><spage>3645</spage><epage>3650</epage><pages>3645-3650</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><abstract>Objective Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects. Data sources The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension"were used for the literature search. Study selection Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed. Results There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCI311)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptodSMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPSl-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension. Conclusion FK506 plays a predominant role in the pathophShysiology of hypertension in solid organ transplantation subjects.</abstract><cop>China</cop><pub>Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China</pub><pmid>25316243</pmid><doi>10.3760/cma.j.issn.0366-6999.20141176</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2014, Vol.127 (20), p.3645-3650
issn 0366-6999
2542-5641
language eng
recordid cdi_wanfang_journals_zhcmj201420022
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects FK506
FKBP12
Humans
Hypertension - chemically induced
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Organ Transplantation - adverse effects
Tacrolimus - adverse effects
Tacrolimus - therapeutic use
分子机制
器官移植
妊高征
实体
患者
蛋白激酶C
title Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A27%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20mechanisms%20of%20FK506-induced%20hypertension%20in%20solid%20organ%20transplantation%20patients&rft.jtitle=Chinese%20medical%20journal&rft.au=Wang,%20Jianglin&rft.date=2014&rft.volume=127&rft.issue=20&rft.spage=3645&rft.epage=3650&rft.pages=3645-3650&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.3760/cma.j.issn.0366-6999.20141176&rft_dat=%3Cwanfang_jour_proqu%3Ezhcmj201420022%3C/wanfang_jour_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1612985371&rft_id=info:pmid/25316243&rft_cqvip_id=662852132&rft_wanfj_id=zhcmj201420022&rfr_iscdi=true